MA44085A - Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants - Google Patents

Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants

Info

Publication number
MA44085A
MA44085A MA044085A MA44085A MA44085A MA 44085 A MA44085 A MA 44085A MA 044085 A MA044085 A MA 044085A MA 44085 A MA44085 A MA 44085A MA 44085 A MA44085 A MA 44085A
Authority
MA
Morocco
Prior art keywords
diamino
alkylamino
bonded
voltage
sodium channels
Prior art date
Application number
MA044085A
Other languages
English (en)
Inventor
Rajan Anand
Thomas J Greshock
Liangqin Guo
Tianying Jian
Michael J Kelly Iii
Ronald M Kim
Mark E Layton
James Mulhearn
Philippe Nantermet
Anthony J Roecker
Deping Wang
Walter Won
Ting Zhang
Gang Zhou
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA44085A publication Critical patent/MA44085A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA044085A 2015-12-18 2016-12-15 Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants MA44085A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562269648P 2015-12-18 2015-12-18
US201662417040P 2016-11-03 2016-11-03
US201662422182P 2016-11-15 2016-11-15

Publications (1)

Publication Number Publication Date
MA44085A true MA44085A (fr) 2021-04-21

Family

ID=59057567

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044085A MA44085A (fr) 2015-12-18 2016-12-15 Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants

Country Status (10)

Country Link
US (1) US10519147B2 (fr)
EP (1) EP3389654B1 (fr)
JP (1) JP2019502688A (fr)
KR (1) KR20180096683A (fr)
CN (1) CN109069489A (fr)
AU (1) AU2016370677A1 (fr)
BR (1) BR112018012408A2 (fr)
CA (1) CA3008614A1 (fr)
MA (1) MA44085A (fr)
WO (1) WO2017106409A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201726637A (zh) 2015-12-18 2017-08-01 默沙東藥廠 對電位閘控鈉通道具選擇活性之羥基烷基胺-及羥基環烷基胺-取代之二胺-芳基磺胺化合物
EP3484464B1 (fr) * 2016-03-22 2020-10-28 Merck Sharp & Dohme Corp. Composés de n1-phénylpropane-1,2-diamine ayant une activité sélective des canaux sodiques sensibles à la tension
KR102366077B1 (ko) 2016-05-20 2022-02-21 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
SG11201903348UA (en) 2016-10-17 2019-05-30 Genentech Inc Therapeutic compounds and methods of use thereof
MA46615A (fr) * 2016-10-27 2019-09-04 Bristol Myers Squibb Co Inhibiteurs de nav1.7 de type acyl-sulfonamide
EP3541373B1 (fr) * 2016-11-17 2023-11-01 Merck Sharp & Dohme LLC Composés d'arylsulfonamide à liaisons diamino-alkylamino présentant une activité sélective dans les canaux sodiques sensibles à la tension
KR20190086772A (ko) 2016-12-09 2019-07-23 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
WO2018175707A1 (fr) 2017-03-24 2018-09-27 Genentech, Inc. Dérivés de 4-pipéridine-n-(pyrimidin-4-yl) chromane-7-sulfonamide en tant qu'inhibiteurs de canaux sodiques
EP3759098A1 (fr) 2018-02-26 2021-01-06 Genentech, Inc. Composés de pyridine-sulfonamide et leur utilisation contre la douleur et les états associés
EP3774801A1 (fr) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Hydro-pyrido-azines substituées utilisées comme inhibiteurs du canal sodique
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
BR112020024729A2 (pt) 2018-06-13 2021-03-23 Xenon Pharmaceuticals, Inc. compostos de benzenossulfonamida e seu uso como agentes terapêuticos
CA3104913A1 (fr) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Composes de sulfonamide substitues par heteroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
IL279810B2 (en) 2018-08-31 2025-03-01 Xenon Pharmaceuticals Inc Heteroaryl-modified sulfonamide compounds and their use as medicinal agents
EP3891157A4 (fr) * 2018-12-05 2022-08-31 Merck Sharp & Dohme Corp. Composés d'aryle sulfonamide substitués par 4-amino ou 4-alcoxy ayant une activité sélective dans des canaux sodiques sensibles à la tension
CN117362206B (zh) * 2023-12-08 2024-02-20 四川大学华西第二医院 一类芳基磺酰胺类化合物、合成方法及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200524888A (en) 2003-08-08 2005-08-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
ATE461177T1 (de) 2007-03-23 2010-04-15 Icagen Inc Ionenkanal-hemmer
HUE025013T2 (hu) * 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
JP2017516803A (ja) 2014-05-30 2017-06-22 ファイザー・インク ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド
WO2016009303A1 (fr) 2014-07-17 2016-01-21 Pfizer Inc. Associations de produits pharmaceutiques comprenant de la gabapentine ou de la prégabaline avec des inhibiteurs de nav1.7
TW201726637A (zh) * 2015-12-18 2017-08-01 默沙東藥廠 對電位閘控鈉通道具選擇活性之羥基烷基胺-及羥基環烷基胺-取代之二胺-芳基磺胺化合物
EP3541373B1 (fr) * 2016-11-17 2023-11-01 Merck Sharp & Dohme LLC Composés d'arylsulfonamide à liaisons diamino-alkylamino présentant une activité sélective dans les canaux sodiques sensibles à la tension

Also Published As

Publication number Publication date
CN109069489A (zh) 2018-12-21
KR20180096683A (ko) 2018-08-29
JP2019502688A (ja) 2019-01-31
CA3008614A1 (fr) 2017-06-22
US10519147B2 (en) 2019-12-31
EP3389654B1 (fr) 2023-08-16
WO2017106409A1 (fr) 2017-06-22
AU2016370677A1 (en) 2018-06-07
BR112018012408A2 (pt) 2018-12-04
US20180362518A1 (en) 2018-12-20
EP3389654A4 (fr) 2019-05-22
EP3389654A1 (fr) 2018-10-24

Similar Documents

Publication Publication Date Title
EP3389654A4 (fr) Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants
EP3737672A4 (fr) Composés benzamide
EP2770995A4 (fr) Composés de benzoxazolinone ayant une activité sélective dans des canaux sodiques voltage-dépendants
MA56008A (fr) Composés et compositions pour traiter des états associés à une activité de nlrp
MA42293A (fr) Composés antibactériens
EP3445750A4 (fr) Composés thérapeutiques
EP3484464A4 (fr) Composés de n1-phénylpropane-1,2-diamine ayant une activité sélective dans des canaux sodiques sensibles à la tension
EP2964221A4 (fr) Composés inhibant l'activité enzymatique de la kinase à répétition riche en leucine
EP2950649A4 (fr) Composés amine ayant une activité anti-inflammatoire, antifongique, antiparasitaire et anticancéreuse
EP2964222A4 (fr) Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
EP3340844A4 (fr) Mélangeur personnel amélioré
EP2964220A4 (fr) Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
EP3317241A4 (fr) Composés inhibiteurs thérapeutiques
MA43155A (fr) Composition de déblocage de nez congestionné présentant une activité antivirale
EP2966327A4 (fr) Structure perfectionnée de robinet à trois voies
DK3295552T3 (da) Effektomformer
EP3728289A4 (fr) Composés optimisés
MA41169A (fr) Composés antibactériens à large spectre d'activité
EP3250230A4 (fr) Modulateurs d'activité du complément
EP3280445A4 (fr) Thérapie génique pour prévenir les réactions à des allergènes
EP3464336A4 (fr) Composés
DK3856406T3 (da) Reaktorkonstruktion
EP3261631C0 (fr) Inhibition de l'activité d'olig2
EP3405231A4 (fr) Connecteurs à usage unique
EP3259254A4 (fr) Composés thérapeutiques